Mind Medicine MindMed

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Mind Medicine (MNMD) reports robust financials and advances in psychedelic research

Mind Medicine (MNMD) showcased strong financials, R&D progress, and strategic advancements in its Q4 2022 earnings call.
The company's focus on safety, responsible distribution, and talent acquisition positions it well for future growth and innovation.
Challenges in patient enrollment, dosing strategies, and commercialization strategies require strategic planning and clear execution for success.

Mind Medicine (MNMD) reports positive trial data and strong financials

Mind Medicine (MNMD) showcases progress in pipeline development with positive trial results and a strong financial position. The company's focus on advancing treatments for brain health disorders and efficient cash management highlights its commitment to growth and innovation.

MindMed (MNMD) reports Q2 loss, progresses on innovative treatments

MindMed (MNMD) is advancing its R&D pipeline with a focus on MM-120 for GAD and MM-402 for Autism spectrum disorder. Financially, the company maintains a strong position with cash reserves for ongoing operations. Emphasis on placebo-controlled research and innovative formulation technologies highlights a commitment to scientific rigor and product development.

Mind Medicine (MNMD) reports strong financials and promising R&D progress

Mind Medicine (MNMD) is making significant strides in developing innovative treatments for mental health disorders, with promising lead candidates MM-120 and MM-402. While facing increased R&D expenses and analyst scrutiny, the company's strong financial position and focus on unmet needs present opportunities for future growth.

MindMed reports positive Phase IIb results for MM120 in GAD

MindMed's financial performance in 2023 reflected a net loss of $95.7 million but maintained a strong cash position of $99.7 million.
The Phase IIb trial results for MM120 in GAD were positive, demonstrating significant reductions in HAM-A scores and high clinical response rates.
While facing challenges in trial design and demonstrating drug effects, MindMed remains focused on innovation and addressing unmet medical needs.
Opportunities lie in expanding product indications, developing new therapies, and engaging with regulatory authorities to advance their pipeline.

MindMed reports strong Q1 earnings, advances transformative treatments

MindMed's financials remain strong with significant cash reserves and positive trial outcomes for MM-120.
Strategic focus on advancing MM-120 and MM-402 programs while exploring market dynamics and treatment expansion.
Challenges include managing expenses to sustain financial health and interpreting trial data for future research.
Opportunities lie in exploring additional indications, commercial planning, and reshaping patient care with transformative treatments.

MindMed reports strong Q2 earnings, advances Phase III programs

Mind Medicine (MNMD) showcased strong performance in Phase III programs, fundraising, and financials, positioning the company well for future growth and clinical advancements.
With a focus on operational efficiency, patient recruitment, and data integrity, MindMed is poised to address unmet needs in brain health disorders and drive market expansion.
Challenges lie in meeting upcoming milestones, global market analysis, and maintaining data integrity in Phase III trials, but opportunities abound in R&D expansion and market penetration strategies.
Overall, MindMed's strategic focus on Phase III trials, regulatory pathways, and market launch strategies sets a clear path for future success and growth in the brain health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 70,000 common shares of the Company (the "Options"), with an effective grant date of September 9, 2024. The Options have an exercise price eq.

MindMed Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences: H.C. Wainwright 26th Annual Global Investment Conference Format: Panel Panel Title: Psychedelics in Psychiatry: Breaking New Ground in Mood Disorders Date and Time: Tue.

MindMed to Participate in September Investor Conferences

COMPASS Pathways

Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks.

Psychedelic Stocks: Focus On Their Cash

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 PM ET Company Participants Robert Barrow - CEO Daniel Karlin - CMO Reid Robison - Senior Principal Investigator, Cedar Clinical Research Conference Call Participants Elaine Kim - Cantor Fitzgerald Brian Abrahams - RBC Capital Markets Rudy Li - Leerink Partners LLC Daniel Hultberg - Oppenheimer Christopher Chen - Robert W. Baird Sumant Kulkarni - Canaccord Genuity Operator Good morning, and welcome to the Mind Medicine Second Quarter 2024 Financial Results and Corporate Update Conference Call.

Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript

MindMed Inc. MNMD, -0.87% said Tuesday it's on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through use of lysergide D-tartrate (LSD) in a clinical setting. MindMed is working on FDA approval for an anxiety therapy using LSD.

MindMed readying Phase III trials for LSD therapy to treat anxiety

Marinus Pharmaceuticals

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense, a leading provider of Modular Open Systems Approach (MOSA) products and mission solutions, announced their team to compete for the U.S. Army's CMOSS Mounted Form Factor (CMFF) program. Led by Pacific Defense, the CMFF team includes state-of-the-art industry technology leaders Thales Defense & Security Inc., BAE, Regal Technology Partners, Palantir and STC, an Arcfield Company. “Our company is purpose-built to drive the open-systems chang.

Pacific Defense Announces US Army CMFF Program Team

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended June 30, 2024, and provided a business update. “Building on the positive momentum from our Phase 2b data for MM120 ODT in GAD, we are excited to be launching our Phase 3 clinical program in GAD later this year and to announce.

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

The Food and Drug Administration rejected Lykos' application to treat PTSD with MDMA therapy. Atai, Compass Pathways, and MindMed are sliding in the wake of the decision.

FDA Rejection of MDMA Therapy Isn't End of Psychedelic-Drug Candidates

Atai Life Sciences BV

Cybin

Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 9,285,511 common shares, without par value, at a public offering price of $7.00 per common share, and, to certain investors, pre-funded warrants to purchase 1,428,775 common shares at a price of $6.999 per pre-funded war.

Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common shares in an underwritten public offering. All of the common shares and pre-funded warrants are being offered by MindMed. Min.

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

The FDA's decision on MDMA therapy for PTSD is imminent, impacting MindMed investors and the psychedelic medicine industry. An FDA advisory committee voted against approving MDMA therapy, causing market volatility and uncertainty for psychedelic stocks. Major psychedelic stocks like MindMed have the fundamentals and growing FDA support to withstand a negative FDA decision on MDMA therapy.

MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will present at Canaccord Genuity's 44th Annual Growth Conference: Canaccord Genuity's 44th Annual Growth Conference Format: Fireside Chat Date and Time: Tuesday, August 13, 2024 at 1:30 PM ET Location: Boston, MA Webcast Li.

MindMed to Present at Canaccord Genuity's 44th Annual Growth Conference

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Tuesday, August 13, 2024, at 8:00 a.m. ET to provide a corporate update and review the Company's results for the second quarter ended June 30, 2024. Listeners can register for the webcast via this link. Analysts wishing to part.

MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Stephanie Fagan, effective today, as Chief Corporate Affairs Officer. Ms. Fagan will serve as a member of the executive team and will oversee public affairs and corporate communications for the Company. “I want to welcome Stephanie to the MindMed team.

MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat mental health disorders, today announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering MM120 (lysergide). MM120 is currently in clinical development for adults with generalized anxiety disorder (GAD) and presents opportunities for treating a range of additional.

MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)

GH Research PLC

The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.

3 Psychedelic Stocks to Ride to the Moon and Beyond

Arcellx

Beam Therapeutics

The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market.

FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective today. “MindMed's inclusion in the Russell Indexes mark an exciting milestone and r.

MindMed to be Included in Russell 2000® and Russell 3000® Indexes

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024. A webcast of the fireside chat will be accessible on MindMed's Investor Relations website starting on June 27,.

MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD. “Following a constructive En.

MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)

Acasti Pharma

Tonix Pharmaceuticals Hld

As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuations and high risk, they offer the potential for impressive gains, especially in a bull market.

Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024

Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.

Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?

Mind Medicine's (MindMed) results from phase 1 investigator-initiated trial, using MM-402 for the treatment of patients with Autism Spectrum Disorder, expected Q2 of 2024. The primary endpoint of the phase 2b MMED008 study met with statistical significance of HAM-A score over a 4-week period; Patients were given MM-120 to treat GAD. The global Generalized Anxiety Disorder treatment market is expected to reach $4.26 billion by 2033.

News for Mind Medicine MindMed Stock (MNMD)